alexa K36, A Synthetic Caffeamide Derivative, Improves The Pathology Of Alzheimer’s Disease In High-fat-diet Plus Streptozotocin-induced Hyperinsulinemic And Hyperglycemic Rats
ISSN: 2161-0509

Journal of Nutritional Disorders & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

JOINT EVENT: 13th International Congress on Advances in Natural Medicines Nutraceuticals & Neurocognition & 14th International Conference on Clinical Nutrition
July 27-29, 2017 Rome, Italy

Pei-Chin Wu, Meng-Shiuan Tu, Rong-Shiuan Tu, Shih-Shiang Lin, Yeuh-Hsiung Kuo, Wen-Chang Chang, Yu-Wen Ting, James Swi-Bea Wu and Szu-Chuan Shen
National Taiwan Normal University, Taiwan
China Medical University, Taiwan
National Taiwan University, Taiwan
Posters & Accepted Abstracts: J Nutr Disorders Ther
DOI: 10.4172/2161-0509-C1-007
Abstract
Type 2 Diabetes Mellitus (T2DM), major caused by obesity and characterized with insulin resistance, is a metabolic disease commonly accompanied with hyperglycemia and hyperinsulinemia. Epidemiology studies have showed that T2DM is a risk factor of Alzheimer’s disease (AD). Previous studies confirmed that caffeamide improves serum glucose and insulin resistance in diabetic animal model. This study aims to investigate the protective effect of caffeamide derivative compound K36 on pathology of AD in the high-fat-diet (HFD)-streptozotocin (STZ)-induced hyperglycemic and hyperinsulinemic rats. The male Wistar rats were fed with High Fat Diet (60% fat of calorie) for 4 weeks were intra-peritoneally (i.p.) injected with STZ (30 mg/kg b.w.) and then served HFD continuously for 8 weeks to induce hyperglycemia (mean serum glucose 224 mg/ dL) and hyperinsulinemia (mean serum insulin 0.35 ug/ml). The HFD-STZ rats were then orally administered with K36 (15 mg/kg b.w.) once a day for 13 weeks. The Morris Water Maze trial was performed for evaluating the improvement of cognitive impairment before rats were sacrificed. The blood biochemical analysis was conducted after the rats were sacrificed. The expressions of hippocampus and cortex insulin signaling and synaptic function related proteins were analyzed by Western blotting. The rats exhibit hyperglycemia and hyperinsulinemia after HFD and STZ induction. The serum total cholesterol (TG) and serum triglyceride (TC) decreased by 37% and 36%, respectively, in K36 treated HFD-STZ rats compared to the HFD-STZ rats (p<0.05). The results from Morris Water Maze suggested that K36 significantly improved the cognitive ability in HFD-STZ rats (p<0.05). Western blotting assay revealed that the protein expression of cerebral insulin receptor (IR), phosphocAMP response element-binding protein (pCREB), brain-derived neurotrophic factor (BDNF), postsynaptic density protein 95 (PSD-95) in K36 treated HFD-STZ rats were significantly increased compared to the HFD-STZ rats (p<0.05). In addition, K36 also suppressed the expression of brain amyloid precursor protein (APP) in HFD-STZ rats. According to the above results, we suggest that K36 may prevent AD progression via alleviating cerebral insulin resistance and ameliorating synaptic plasticity in HFD-STZ-induced hyperglycemic and hyperinsulinemic rats.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords